Blockade of IL-6 signaling decreases inflammation in PD-1 signal inhibition-provoked psoriasis-like dermatitis, and specifically, causes a reduction in the levels of Th17-related cytokines in a murine model of IMQ-induced psoriasis-like dermatitis. Here, IL6 is linked to skin disorder.